Barry Investment Advisors Lowers stake in Merck & Co. (MRK)

Merck & Co. (MRK) : Barry Investment Advisors reduced its stake in Merck & Co. by 0.87% during the most recent quarter end. The investment management company now holds a total of 141,564 shares of Merck & Co. which is valued at $8,355,107 after selling 1,246 shares in Merck & Co. , the firm said in a disclosure report filed with the SEC on Jul 14, 2016.Merck & Co. makes up approximately 3.18% of Barry Investment Advisors’s portfolio.

Other Hedge Funds, Including , Live Your Vision reduced its stake in MRK by selling 538 shares or 1.02% in the most recent quarter. The Hedge Fund company now holds 52,022 shares of MRK which is valued at $3,070,338. Merck & Co. makes up approx 1.37% of Live Your Vision’s portfolio.Cornerstone Investment Partners reduced its stake in MRK by selling 121 shares or 0.71% in the most recent quarter. The Hedge Fund company now holds 16,950 shares of MRK which is valued at $1,009,373. Merck & Co. makes up approx 0.03% of Cornerstone Investment Partners’s portfolio.Svenska Handelsbanken Ab (publ) boosted its stake in MRK in the latest quarter, The investment management firm added 935,529 additional shares and now holds a total of 1,009,529 shares of Merck & Co. which is valued at $60,117,452. Merck & Co. makes up approx 3.59% of Svenska Handelsbanken Ab (publ)’s portfolio.Firstmerit Bank N A Trustee reduced its stake in MRK by selling 6,990 shares or 2.93% in the most recent quarter. The Hedge Fund company now holds 231,280 shares of MRK which is valued at $13,772,724. Merck & Co. makes up approx 1.09% of Firstmerit Bank N A Trustee’s portfolio.Thompson Rubinstein Investment Management Inc Or boosted its stake in MRK in the latest quarter, The investment management firm added 360 additional shares and now holds a total of 12,439 shares of Merck & Co. which is valued at $738,255. Merck & Co. makes up approx 0.28% of Thompson Rubinstein Investment Management Inc Or’s portfolio.

Merck & Co. closed down -0.61 points or -1.02% at $59.02 with 87,69,171 shares getting traded on Monday. Post opening the session at $59, the shares hit an intraday low of $58.715 and an intraday high of $59.49 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Leave a Reply

Merck & Co. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Merck & Co.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.